Genomics companies analyze and interpret genetic information to uncover insights about genetic variations and disease mechanisms and develop tests, therapies and technologies to advance personalized medicine. Companies...
What's going on with CRISPR Therapeutics (NASDAQ: CRSP) ? The company's shares have been southbound for the better part of three years. And despite major regulatory wins since late 2023, the biotech hasn't...
CRISPR Therapeutics (NASDAQ: CRSP) isn't a stock that's wanting for reasons to invest. Between the solid launch of its first commercialized therapy and a promising pipeline that's continuing to deliver,...
Investors looking for stocks that can make dramatic gains can find some in the biopharmaceutical industry. Right now, there are a pair of biopharma stocks that Wall Street expects to rocket higher in 2025....
CRISPR Therapeutics (NASDAQ: CRSP) is recognized as a pioneer in the field of gene therapy. This biotechnology has the potential to revolutionize medicine through precise modifications of a person's DNA...
Preliminary data show CTX112™ may benefit patients with certain B-cell malignancies; RMAT designation granted by FDA.Quiver AI SummaryCRISPR Therapeutics announced that preliminary data from its Phase...
The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% this year compared to 28% for the S&P 500 . Will that trend continue in 2025?...
It's getting harder these days to find great growth stocks trading for less than $100 a share. It almost seems like a higher price is one of the criteria. But investors should know that there are plenty...
Ark Invest chief Cathie Wood is known for scooping up shares of innovators early in their growth stories and holding on for the long term. The idea is to get in on these players for a bargain price, and...
On Nov. 21, shares of CRISPR Therapeutics (NASDAQ: CRSP) were down 47% from a peak they reached in March. This might be a little surprising to folks who have been following this developer of gene therapies....